Design of Synthetic Surrogates for the Macrolactone Linker Motif in Coibamide A-Reference-Cited by-同舟云学术

Design of Synthetic Surrogates for the Macrolactone Linker Motif in Coibamide A

Published:2023-09-19 Issue:10 Volume:14 Page:1344-1350
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Suzuki Rikito¹²,Mattos Daphne R.³,Kitamura Takashi¹,Tsujioka Rina²,Kobayashi Kazuya²^ORCID,Inuki Shinsuke¹^ORCID,Ohno Hiroaki¹^ORCID,Ishmael Jane E.³^ORCID,McPhail Kerry L.³^ORCID,Oishi Shinya¹²^ORCID

Affiliation:

1. Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan

2. Laboratory of Medicinal Chemistry, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto 607-8412, Japan

3. Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, Oregon 97331, United States

Funder

Takeda Science Foundation

Japan Agency for Medical Research and Development

Japan Society for the Promotion of Science

National Institute of General Medical Sciences

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.3c00232

Reference37 articles.

1. Coibamide A, a Potent Antiproliferative Cyclic Depsipeptide from the Panamanian Marine Cyanobacterium Leptolyngbya sp.

2. Efficient Synthesis and Stereochemical Revision of Coibamide A

3. Coibamide A Targets Sec61 to Prevent Biogenesis of Secretory and Membrane Proteins

4. Coibamide A, a natural lariat depsipeptide, inhibits VEGFA/VEGFR2 expression and suppresses tumor growth in glioblastoma xenografts

5. Targeting of HER/ErbB family proteins using broad spectrum Sec61 inhibitors coibamide A and apratoxin A